Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction
about
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virusNTCP and beyond: opening the door to unveil hepatitis B virus entryThe hepatitis B virus preS1 domain hijacks host trafficking proteins by motif mimicryApplications of human hepatitis B virus preS domain in bio- and nanotechnology.The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virusPurinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus.Emerging antivirals for the treatment of hepatitis B.Strategies to eliminate HBV infection.Proteoglycans act as cellular hepatitis delta virus attachment receptors.Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expressionSelection of HBV preS1-binding penta-peptides by phage display.Cholesterol depletion of hepatoma cells impairs hepatitis B virus envelopment by altering the topology of the large envelope proteinInhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals.Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine.Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis.Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice.Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes.Pharmacologically triggered hydrogel for scheduling hepatitis B vaccine administration.A novel toolbox for the in vitro assay of hepatitis D virus infection.Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection.Hepatitis B core-based virus-like particles to present heterologous epitopes.Recent insights into hepatitis B virus-host interactions.Treatment of hepatitis B virus: an update.Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.High expression of beta2-glycoprotein I is associated significantly with the earliest stages of hepatitis B virus infection.Bile Acid Uptake Transporters as Targets for Therapy.Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen.The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly.Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes.Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts.Long-term hepatitis B infection in a scalable hepatic co-culture system.Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism.Antibody-mediated immunotherapy against chronic hepatitis B virus infection.Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver.Recent advances in managing hepatitis DProductive HBV infection of well-differentiated, hNTCP-expressing human hepatoma-derived (Huh7) cells.Upregulation of sodium taurocholate cotransporter polypeptide during hepatogenic differentiation of umbilical cord matrix mesenchymal stem cells facilitates hepatitis B entry.In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy.Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
P2860
Q21128797-7C34FEA7-58BE-4234-AD06-1CE1E81538CEQ26999712-342B5423-D0EA-47BC-B3A2-030A7F461EA3Q27685219-2D586E44-F3F0-4D6F-B238-C8AE75F600DAQ27693188-20C4B0C9-C121-46B1-8792-8E4F3E2E51E2Q28476762-F08EDC52-78E5-4092-9710-DEDDFC7E1687Q33781062-956C6381-6837-49B8-B7FB-B279142F3A92Q33801328-287E62B3-22DA-4980-BD67-BFCEC6D89C26Q34308129-6B5E6251-AFF6-4A6F-8545-A35DE18EB19DQ34625734-03EA5AC5-E402-46E3-91C0-5EBBCFC58C79Q35126674-62176B76-0F9B-4639-9697-0F1728373FC2Q35195132-B58C0F8A-D9D9-484D-9F72-2971573B85A6Q35599384-55B017C1-8082-4D2E-857A-8995B6011F30Q35926878-D97512E7-4EE5-457B-BA89-193AEB87F9FCQ36109563-C1D9FE0C-DC44-496A-883A-3D465C258A57Q36154830-64CC716A-6802-4B8D-A201-6FF28620F8D5Q36311265-48A22FFA-1285-4F66-9A29-FE5DAB147378Q36911797-4191AA83-0059-458F-9974-48AFD0A6AB29Q37158131-46833305-1519-4292-AB14-C3C7C5132AC0Q37581726-38F623F2-8010-4A97-A40E-4D00D95C3FCDQ37736696-9C0E8DD0-0800-4D57-BDB5-CE8C73CDD303Q38081969-FBE13CE4-365D-498C-B428-25AEEA96953CQ38194061-0B73E96E-7115-4E64-AE36-39B55C62C0ABQ38794446-A937167E-E9EB-4157-9B9D-AFC0CB8D0151Q38837061-905EB316-C7AD-4FDF-93B2-DF9CF3612544Q39001579-6AF7932C-86AE-4DDB-8CD3-F884B321A8BFQ39156569-148E22D0-C248-47C1-A45D-4095315CCEE8Q39414876-D313A355-91F8-4A90-A96C-D294AA4971B2Q39744156-3BE5245A-E7EE-4395-A8FA-C2E2AF7CB9BDQ40004593-B71399F6-EFC7-437F-8946-7F858B303080Q40078603-1B7EDEA0-FBAB-4963-BCB4-828548CCE0D3Q40084188-EF6F4DEC-96C8-44C4-81A5-4A1CDE02E2CDQ40108579-D1FCB67E-87FD-4213-80C3-61E8314A6208Q40183159-283A3008-464D-4779-AEBE-57269A66F9A1Q40196246-C81113AD-6692-4AF2-A84A-815AC21C919AQ40640234-F598B7B4-32E8-4DB0-B142-E7C0A13C6F34Q41588940-B79707EE-7385-4961-98C5-13C5D6EA2006Q41925781-226A9B85-2784-4A64-AB55-343E4940D09BQ41927740-178FEA65-D5E9-46DB-9235-B987CF0BF524Q42210069-D537BE02-3096-4293-A21A-43B2CA58C28CQ43940290-5BCC134C-B23E-42A8-964C-E66302A91C7D
P2860
Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@ast
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@en
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@nl
type
label
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@ast
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@en
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@nl
prefLabel
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@ast
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@en
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@nl
P2093
P2860
P3181
P356
P1433
P1476
Fine mapping of pre-S sequence ...... -mediated receptor interaction
@en
P2093
Alexa Schieck
Andreas Schulze
Stephan Urban
P2860
P304
P3181
P356
10.1128/JVI.01902-09
P407
P50
P577
2010-02-01T00:00:00Z